Erythroid proliferations in myeloid neoplasms

作者: Sa A. Wang , Robert P. Hasserjian

DOI: 10.1016/J.HUMPATH.2011.08.008

关键词:

摘要: Prominent erythroid proliferations (in which elements comprise ≥50% of total bone marrow cells) can be seen in various hematopoietic stem cell neoplasms. The myeloproliferative neoplasm polycythemia vera exhibits effective, overexuberant erythropoiesis resulting an increased red blood mass; contrast, most other diseases characterized by predominance exhibit ineffective hemopoiesis. latter include acute leukemia (erythroid-myeloid and pure subtypes) as well some cases myelodysplastic syndromes, myeloid with myelodysplasia-related changes, therapy-related Some nonneoplastic reactive conditions may also manifest a striking predominance. In this article, we review the literature relevant to group for better understanding their clinicopathologic features surrounding controversies. We examine position neoplastic current 2008 World Health Organization Classification Myeloid Neoplasms provide recommendations how approach differential diagnosis diseases.

参考文章(62)
K S Yoon, J H Ahn, J T Suh, M J Kim, W I Lee, C G Ihm, T W Lee, Bone marrow findings before and after treatment with recombinant human erythropoietin in chronic hemodialyzed patients. Clinical Nephrology. ,vol. 43, pp. 189- 195 ,(1995)
Joris Loup Andrieux, Jean Loup Demory, Karyotype and molecular cytogenetic studies in polycythemia vera. Current hematology reports. ,vol. 4, pp. 224- 229 ,(2005)
Peter Greenberg, Christopher Cox, Michelle M. LeBeau, Pierre Fenaux, Pierre Morel, Guillermo Sanz, Miguel Sanz, Teresa Vallespi, Terry Hamblin, David Oscier, Kazuma Ohyashiki, Keisuke Toyama, Carlo Aul, Ghulam Mufti, John Bennett, International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes Blood. ,vol. 89, pp. 2079- 2088 ,(1997) , 10.1182/BLOOD.V89.6.2079
Lowe Jg, Johnston Rn, Sharp Ra, ANTI-TUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA The British journal of clinical practice. ,vol. 44, pp. 706- 707 ,(1990)
David Grimwade, Helen Walker, Fiona Oliver, Keith Wheatley, Christine Harrison, Georgina Harrison, John Rees, Ian Hann, Richard Stevens, Alan Burnett, Anthony Goldstone, The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial Blood. ,vol. 92, pp. 2322- 2333 ,(1998) , 10.1182/BLOOD.V92.7.2322
Elias Campo, N Lee Harris, Elaine S Jaffe, Stefano A Pileri, Harald Stein, Jurgen Thiele, James W Vardiman, None, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ,(2017)
M J Keating, R S Walters, T L Smith, A Cork, K B McCredie, E J Freireich, H M Kantarjian, Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. Journal of Clinical Oncology. ,vol. 4, pp. 1748- 1757 ,(1986) , 10.1200/JCO.1986.4.12.1748
Norbert Gattermann, Andrea Kuendgen, Corinna Strupp, Sabine Knipp, Aristoteles Giagounidis, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, Carlo Aul, Shadi Isa, Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes Haematologica. ,vol. 91, pp. 1596- 1604 ,(2006) , 10.3324/%X
Fermina M Mazzella, Areta Kowal-Vern, M Atef Shrit, James T Rector, James D Cotelingam, Harold R Schumacher, Effects of multidrug resistance gene expression in acute erythroleukemia. Modern Pathology. ,vol. 13, pp. 407- 413 ,(2000) , 10.1038/MODPATHOL.3880070
Wei Liu, Robert P Hasserjian, Ying Hu, Liping Zhang, Roberto N Miranda, L Jeffrey Medeiros, Sa A Wang, Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Modern Pathology. ,vol. 24, pp. 375- 383 ,(2011) , 10.1038/MODPATHOL.2010.194